Biological therapies for psoriasis

Expert Opinion on Biological Therapy

Volumn 13, Issue 12, 2013, Pages 1715-1730

  Mansouri, Bobbak ^a   Patel, Mahir ^a   Menter, Alan ^a  

^a BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Biological therapy; Biosimilar pharmaceuticals; Comorbidities; Interleukin 17; Interleukin 23; Psoriasis; T helper 17 cells; Tumor necrosis factor

Indexed keywords

ABGN 168H; ADALIMUMAB; ANTIPSORIASIS AGENT; ASKP 1240; BI 655066; BIOLOGICAL PRODUCT; BIOSIMILAR AGENT; BRIAKINUMAB; BRODALUMAB; BT 061; CD40 LIGAND MONOCLONAL ANTIBODY; ETANERCEPT; FEZAKINUMAB; GUSELKUMAB; INFLIXIMAB; INTERLEUKIN 17; INTERLEUKIN 22; INTERLEUKIN 23; INTERLEUKIN 23 ANTIBODY; INTERLEUKIN 23P19; IXEKIZUMAB; MK 3222; SCH 900222; SECUKINUMAB; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; UNCLASSIFIED DRUG; USTEKINUMAB;

BIOLOGICAL THERAPY; CARDIOVASCULAR DISEASE; COMORBIDITY; DRUG EFFICACY; DRUG SAFETY; HUMAN; IMMUNOPATHOGENESIS; INFLAMMATORY DISEASE; PHARMACOGENOMICS; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PSORIASIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; TH17 CELL;

BIOLOGICAL FACTORS; BIOLOGICAL THERAPY; HUMANS; PSORIASIS; TREATMENT OUTCOME;

EID: 84887914464     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712598.2013.853739     Document Type: Review

References (157)

1. Christophers E. Psoriasis-epidemiology and clinical spectrum. Clin Exp Dermatol 2001;26(4):314-20
2. Parisi R, Symmons DP, Griffiths CE, Ashcroft DM. Global epidemiology of psoriasis: A systematic review of incidence and prevalence. J Invest Dermatol 2013;133(2):377-85
3. Griffiths CE, Christophers E, Barker JN, et al. A classification of psoriasis vulgaris according to phenotype. Br J Dermatol 2007;156(2):258-62
4. Menter A, Gottlieb A, Feldman SR, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics. J Am Acad Dermatol 2008;58(5):826-50
5. Gelfand JM, Neimann AL, Shin DB, et al. Risk of myocardial infarction in patients with psoriasis. JAMA 2006;296(14):1735-41
6. Neimann AL, Shin DB, Wang X, et al. Prevalence of cardiovascular risk factors in patients with psoriasis. J Am Acad Dermatol 2006;55(5):829-35
7. Herron MD, Hinckley M, Hoffman MS, et al. Impact of obesity and smoking on psoriasis presentation and management. Arch Dermatol 2005;141(12):1527-34
8. Setty AR, Curhan G, Choi HK. Obesity, waist circumference, weight change, and the risk of psoriasis in women: Nurses' Health Study II. Arch Intern Med 2007;167(15):1670-5
9. Sterry W, Strober BE, Menter A. Obesity in psoriasis: The metabolic, clinical and therapeutic implications. Report of an interdisciplinary conference and review. Br J Dermatol 2007;157(4):649-55
10. Armstrong AW. Do TNF inhibitors reduce the risk of myocardial infarction in psoriasis patients? JAMA 2013;309(19):2043-4
11. Gisondi P, Tessari G, Conti A, et al. Prevalence of metabolic syndrome in patients with psoriasis: A hospital-based case-control study. Br J Dermatol 2007;157(1):68-73
12. Henseler T, Christophers E. Disease concomitance in psoriasis. J Am Acad Dermatol 1995;32(6):982-6
13. Menter A, Griffiths CE. Current and future management of psoriasis. Lancet 2007;370(9583):272-84
14. American Academy of Dermatology Work G, Menter A, Korman NJ, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 6. Guidelines of care for the treatment of psoriasis and psoriatic arthritis: Case-based presentations and evidence-based conclusions. J Am Acad Dermatol 2011;65(1):137-74
15. Nestle FO, Kaplan DH, Barker J. Psoriasis. N Engl J Med 2009;361(5):496-509
16. Kryczek I, Bruce AT, Gudjonsson JE, et al. Induction of IL-17+ T cell trafficking and development by IFNgamma: Mechanism and pathological relevance in psoriasis. J Immunol 2008;181(7):4733-41
17. Girolomoni G, Mrowietz U, Paul C. Psoriasis: Rationale for targeting interleukin-17. Br J Dermatol 2012;167(4):717-24
18. Quatresooz P, Hermanns-Le T, Pierard GE, et al. Ustekinumab in psoriasis immunopathology with emphasis on the Th17-IL23 axis: A primer. J Biomed Biotechnol 2012;2012:147413
19. Pene J, Chevalier S, Preisser L, et al. Chronically inflamed human tissues are infiltrated by highly differentiated Th17 lymphocytes. J Immunol 2008;180(11):7423-30
20. Yawalkar N, Karlen S, Hunger R, et al. Expression of interleukin-12 is increased in psoriatic skin. J Invest Dermatol 1998;111(6):1053-7
21. Yawalkar N, Tscharner GG, Hunger RE, Hassan AS. Increased expression of IL-12p70 and IL-23 by multiple dendritic cell and macrophage subsets in plaque psoriasis. J Dermatol Sci 2009;54(2):99-105
22. Piskin G, Sylva-Steenland RM, Bos JD, Teunissen MB. In vitro and in situ expression of IL-23 by keratinocytes in healthy skin and psoriasis lesions: Enhanced expression in psoriatic skin. J Immunol 2006;176(3):1908-15
23. Lee E, Trepicchio WL, Oestreicher JL, et al. Increased expression of interleukin 23 p19 and p40 in lesional skin of patients with psoriasis vulgaris. J Exp Med 2004;199(1):125-30
24. Pierard GE, Pierard-Franchimont C, Szepetiuk G, et al. The therapeutic potential of TNF-alpha antagonists for skin psoriasis comorbidities. Expert Opin Biol Ther 2010;10(8):1197-208
25. Calabrese LH. Molecular differences in anticytokine therapies. Clin Exp Rheumatol 2003;21(2):241-8
26. Rau R. Adalimumab (a fully human anti-tumour necrosis factor alpha monoclonal antibody) in the treatment of active rheumatoid arthritis: The initial results of five trials. Ann Rheum Dis 2002;61(Suppl 2):ii70-3
27. Humira [package insert]. AbbVie, Inc; North Chicago, IL: 2013
28. Menter A, Tyring SK, Gordon K, et al. Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial. J Am Acad Dermatol 2008;58(1):106-15 double-blind, placebo-controlled study in 1212 subjects
29. Kimball AB, Yu AP, Signorovitch J, et al. The effects of adalimumab treatment and psoriasis severity on self-reported work productivity and activity impairment for patients with moderate to severe psoriasis. J Am Acad Dermatol 2012;66(2):e67-76
30. Menter A, Gordon KB, Leonardi CL, et al. Efficacy and safety of adalimumab across subgroups of patients with moderate to severe psoriasis. J Am Acad Dermatol 2010;63(3):448-56
31. Gordon K, Papp K, Poulin Y, et al. Long-term efficacy and safety of adalimumab in patients with moderate to severe psoriasis treated continuously over 3 years: Results from an open-label extension study for patients from REVEAL. J Am Acad Dermatol 2012;66(2):241-51
32. Papp K, Menter A, Poulin Y, et al. Long-term outcomes of interruption and retreatment vs. continuous therapy with adalimumab for psoriasis: Subanalysis of REVEAL and the open-label extension study. J Eur Acad Dermatol Venereol 2013;27(5):634-42
33. Leonardi C, Sobell JM, Crowley JJ, et al. Efficacy, safety and medication cost implications of adalimumab 40 mg weekly dosing in patients with psoriasis with suboptimal response to 40 mg every other week dosing: Results from an open-label study. Br J Dermatol 2012;167(3):658-67
34. Saurat JH, Stingl G, Dubertret L, et al. Efficacy and safety results from the randomized controlled comparative study of adalimumab vs. methotrexate vs. placebo in patients with psoriasis (CHAMPION). Br J Dermatol 2008;158(3):558-66
35. Revicki D, Willian MK, Saurat JH, et al. Impact of adalimumab treatment on health-related quality of life and other patient-reported outcomes: Results from a 16-week randomized controlled trial in patients with moderate to severe plaque psoriasis. Br J Dermatol 2008;158(3):549-57
36. Reich K, Signorovitch J, Ramakrishnan K, et al. Benefit-risk analysis of adalimumab versus methotrexate and placebo in the treatment of moderate to severe psoriasis: Comparison of adverse event-free response days in the CHAMPION trial. J Am Acad Dermatol 2010;63(6):1011-18
37. Ortonne JP, Chimenti S, Reich K, et al. Efficacy and safety of adalimumab in patients with psoriasis previously treated with anti-tumour necrosis factor agents: Subanalysis of BELIEVE. J Eur Acad Dermatol Venereol 2011;25(9):1012-20
38. Thaci D, Ortonne JP, Chimenti S, et al. A phase IIIb, multicentre, randomized, double-blind, vehicle-controlled study of the efficacy and safety of adalimumab with and without calcipotriol/ betamethasone topical treatment in patients with moderate to severe psoriasis: The BELIEVE study. Br J Dermatol 2010;163(2):402-11
39. Rigopoulos D, Gregoriou S, Lazaridou E, et al. Treatment of nail psoriasis with adalimumab: An open label unblinded study. J Eur Acad Dermatol Venereol 2010;24(5):530-4
40. Leonardi C, Langley RG, Papp K, et al. Adalimumab for treatment of moderate to severe chronic plaque psoriasis of the hands and feet: Efficacy and safety results from REACH, a randomized, placebo-controlled, double-blind trial. Arch Dermatol 2011;147(4):429-36
41. Bissonnette R, Bolduc C, Poulin Y, et al. Efficacy and safety of adalimumab in patients with plaque psoriasis who have shown an unsatisfactory response to etanercept. J Am Acad Dermatol 2010;63(2):228-34
42. Van Lumig PP, Lecluse LL, Driessen RJ, et al. Switching from etanercept to adalimumab is effective and safe: Results in 30 patients with psoriasis with primary failure, secondary failure or intolerance to etanercept. Br J Dermatol 2010;163(4):838-46
43. Martyn-Simmons CL, Green L, Ash G, et al. Adalimumab for psoriasis patients who are non-responders to etanercept: Open-label prospective evaluation. J Eur Acad Dermatol Venereol 2009;23(12):1394-7
44. Bissonnette R, Tardif JC, Harel F, et al. Effects of the tumor necrosis factor-alpha antagonist adalimumab on arterial inflammation assessed by positron emission tomography in patients with psoriasis: Results of a randomized controlled trial. Circ Cardiovasc Imaging 2013;6(1):83-90
45. Burmester GR, Panaccione R, Gordon KB, et al. Adalimumab: Long-term safety in 23 458 patients from global clinical trials in rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, psoriatic arthritis, psoriasis and Crohn's disease. Ann Rheum Dis 2013;72(4):517-24
46. Peppel K, Crawford D, Beutler B. A tumor necrosis factor (TNF) receptor-IgG heavy chain chimeric protein as a bivalent antagonist of TNF activity. J Exp Med 1991;174(6):1483-9
47. Enbrel [package insert]. Immunex Corp; Thousand Oaks, CA: 2013
48. Mease PJ, Goffe BS, Metz J, et al. Etanercept in the treatment of psoriatic arthritis and psoriasis: A randomised trial. Lancet 2000;356(9227):385-90
49. Leonardi CL, Powers JL, Matheson RT, et al. Etanercept as monotherapy in patients with psoriasis. N Engl J Med 2003;349(21):2014-22
50. Gottlieb AB, Matheson RT, Lowe N, et al. A randomized trial of etanercept as monotherapy for psoriasis. Arch Dermatol 2003;139(12):1627-32; discussion 32
51. Papp KA, Tyring S, Lahfa M, et al. A global phase III randomized controlled trial of etanercept in psoriasis: Safety, efficacy, and effect of dose reduction. Br J Dermatol 2005;152(6):1304-12
52. van de Kerkhof PC, Segaert S, Lahfa M, et al. Once weekly administration of etanercept 50 mg is efficacious and well tolerated in patients with moderate-to-severe plaque psoriasis: A randomized controlled trial with open-label extension. Br J Dermatol 2008;159(5):1177-85
53. Krueger GG, Langley RG, Finlay AY, et al. Patient-reported outcomes of psoriasis improvement with etanercept therapy: Results of a randomized phase III trial. Br J Dermatol 2005;153(6):1192-9
54. Feldman SR, Kimball AB, Krueger GG, et al. Etanercept improves the health-related quality of life of patients with psoriasis: Results of a phase III randomized clinical trial. J Am Acad Dermatol 2005;53(5):887-9
55. Tyring S, Gottlieb A, Papp K, et al. Etanercept and clinical outcomes, fatigue, and depression in psoriasis: Double-blind placebo-controlled randomised phase III trial. Lancet 2006;367(9504):29-35
56. Krishnan R, Cella D, Leonardi C, et al. Effects of etanercept therapy on fatigue and symptoms of depression in subjects treated for moderate to severe plaque psoriasis for up to 96 weeks. Br J Dermatol 2007;157(6):1275-7
57. Moore A, Gordon KB, Kang S, et al. A randomized, open-label trial of continuous versus interrupted etanercept therapy in the treatment of psoriasis. J Am Acad Dermatol 2007;56(4):598-603
58. Dauden E, Griffiths CE, Ortonne JP, et al. Improvements in patient-reported outcomes in moderate-to-severe psoriasis patients receiving continuous or paused etanercept treatment over 54 weeks: The CRYSTEL study. J Eur Acad Dermatol Venereol 2009;23(12):1374-82
59. Ortonne JP, Taieb A, Ormerod AD, et al. Patients with moderate-to-severe psoriasis recapture clinical response during re-treatment with etanercept. Br J Dermatol 2009;161(5):1190-5
60. Papoutsaki M, Costanzo A, Mazzotta A, et al. Etanercept for the treatment of severe childhood psoriasis. Br J Dermatol 2006;154(1):181-3
61. Paller AS, Siegfried EC, Langley RG, et al. Etanercept treatment for children and adolescents with plaque psoriasis. N Engl J Med 2008;358(3):241-51
62. Landells I, Paller AS, Pariser D, et al. Efficacy and safety of etanercept in children and adolescents aged > or = 8 years with severe plaque psoriasis. Eur J Dermatol 2010;20(3):323-8
63. Paller AS, Siegfried EC, Eichenfield LF, et al. Long-term etanercept in pediatric patients with plaque psoriasis. J Am Acad Dermatol 2010;63(5):762-8
64. Langley RG, Paller AS, Hebert AA, et al. Patient-reported outcomes in pediatric patients with psoriasis undergoing etanercept treatment: 12-week results from a phase III randomized controlled trial. J Am Acad Dermatol 2011;64(1):64-70
65. Bagel J, Lynde C, Tyring S, et al. Moderate to severe plaque psoriasis with scalp involvement: A randomized, double-blind, placebo-controlled study of etanercept. J Am Acad Dermatol 2012;67(1):86-92
66. Esposito M, Mazzotta A, de Felice C, et al. Treatment of erythrodermic psoriasis with etanercept. Br J Dermatol 2006;155(1):156-9
67. Gottlieb AB, Langley RG, Strober BE, et al. A randomized, double-blind, placebo-controlled study to evaluate the addition of methotrexate to etanercept in patients with moderate to severe plaque psoriasis. Br J Dermatol 2012;167(3):649-57
68. Zachariae C, Mork NJ, Reunala T, et al. The combination of etanercept and methotrexate increases the effectiveness of treatment in active psoriasis despite inadequate effect of methotrexate therapy. Acta Derm Venereol 2008;88(5):495-501
69. Gisondi P, Del Giglio M, Cotena C, Girolomoni G. Combining etanercept and acitretin in the therapy of chronic plaque psoriasis: A 24-week, randomized, controlled, investigator-blinded pilot trial. Br J Dermatol 2008;158(6):1345-9
70. Gambichler T, Tigges C, Scola N, et al. Etanercept plus narrowband ultraviolet B phototherapy of psoriasis is more effective than etanercept monotherapy at 6 weeks. Br J Dermatol 2011;164(6):1383-6
71. Kimball AB, Pariser D, Yamauchi PS, et al. OBSERVE-5 interim analysis: An observational postmarketing safety registry of etanercept for the treatment of psoriasis. J Am Acad Dermatol 2013;68(5):756-64
72. Papp KA, Poulin Y, Bissonnette R, et al. Assessment of the long-term safety and effectiveness of etanercept for the treatment of psoriasis in an adult population. J Am Acad Dermatol 2012;66(2):e33-45
73. Xie X, Li F, Chen JW, Wang J. Risk of tuberculosis infection in anti-TNF-alpha biological therapy: From bench to bedside. J Microbiol Immunol Infect 2013; Epub ahead of print
74. Scallon BJ, Moore MA, Trinh H, et al. Chimeric anti-TNF-alpha monoclonal antibody cA2 binds recombinant transmembrane TNF-alpha and activates immune effector functions. Cytokine 1995;7(3):251-9
75. Remicade [package insert]. Janssen Biotech, Inc; Horsham, PA: 2013
76. Gottlieb AB, Evans R, Li S, et al. Infliximab induction therapy for patients with severe plaque-type psoriasis: A randomized, double-blind, placebo-controlled trial. J Am Acad Dermatol 2004;51(4):534-42
77. Reich K, Nestle FO, Papp K, et al. Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: A phase III, multicentre, double-blind trial. Lancet 2005;366(9494):1367-74
78. Menter A, Feldman SR, Weinstein GD, et al. A randomized comparison of continuous vs. intermittent infliximab maintenance regimens over 1 year in the treatment of moderate-to-severe plaque psoriasis. J Am Acad Dermatol 2007;56(1):31; e1-15
79. Reich K, Wozel G, Zheng H, et al. Efficacy and safety of infliximab as continuous or intermittent therapy in patients with moderate-to-severe plaque psoriasis: Results of a randomised, long-term extension trial (RESTORE2). Br J Dermatol 2013;168(6):1325-34
80. Barker J, Hoffmann M, Wozel G, et al. Efficacy and safety of infliximab vs. methotrexate in patients with moderate-to-severe plaque psoriasis: Results of an open-label, active-controlled, randomized trial (RESTORE1). Br J Dermatol 2011;165(5):1109-17
81. Feldman SR, Gordon KB, Bala M, et al. Infliximab treatment results in significant improvement in the quality of life of patients with severe psoriasis: A double-blind placebo-controlled trial. Br J Dermatol 2005;152(5):954-60
82. Reich K, Nestle FO, Papp K, et al. Improvement in quality of life with infliximab induction and maintenance therapy in patients with moderate-to-severe psoriasis: A randomized controlled trial. Br J Dermatol 2006;154(6):1161-8
83. Feldman SR, Gottlieb AB, Bala M, et al. Infliximab improves health-related quality of life in the presence of comorbidities among patients with moderate-to-severe psoriasis. Br J Dermatol 2008;159(3):704-10
84. Gottlieb AB, Kalb RE, Blauvelt A, et al. The efficacy and safety of infliximab in patients with plaque psoriasis who had an inadequate response to etanercept: Results of a prospective, multicenter, open-label study. J Am Acad Dermatol 2012;67(4):642-50
85. Bissonnette R, Poulin Y, Guenther L, et al. Treatment of palmoplantar psoriasis with infliximab: A randomized, double-blind placebo-controlled study. J Eur Acad Dermatol Venereol 2011;25(12):1402-8
86. Rich P, Griffiths CE, Reich K, et al. Baseline nail disease in patients with moderate to severe psoriasis and response to treatment with infliximab during 1 year. J Am Acad Dermatol 2008;58(2):224-31
87. Kamili QU, Miner A, Hapa A, Menter A. Infliximab treatment for psoriasis in 120 patients on therapy for a minimum of one year: A review. J Drugs Dermatol 2011;10(5):539-44
88. Torii H, Nakagawa H. Infliximab monotherapy in Japanese patients with moderate-to-severe plaque psoriasis and psoriatic arthritis. A randomized, double-blind, placebo-controlled multicenter trial. J Dermatol Sci 2010;59(1):40-9
89. Rustin MH. Long-term safety of biologics in the treatment of moderate-to-severe plaque psoriasis: Review of current data. Br J Dermatol 2012;167(Suppl 3):3-11
90. Scanlon JV, Exter BP, Steinberg M, Jarvis CI. Ustekinumab: Treatment of adult moderate-to-severe chronic plaque psoriasis. Ann Pharmacother 2009;43(9):1456-65
91. Stelara [package insert]. Janssen Biotech, Inc; Horsham, PA: 2013
92. Leonardi CL, Kimball AB, Papp KA, et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1). Lancet 2008;371(9625):1665-74
93. Papp KA, Langley RG, Lebwohl M, et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2). Lancet 2008;371(9625):1675-84
94. Lebwohl M, Yeilding N, Szapary P, et al. Impact of weight on the efficacy and safety of ustekinumab in patients with moderate to severe psoriasis: Rationale for dosing recommendations. J Am Acad Dermatol 2010;63(4):571-9
95. Kimball AB, Papp KA, Wasfi Y, et al. Long-term efficacy of ustekinumab in patients with moderate-to-severe psoriasis treated for up to 5 years in the PHOENIX 1 study. J Eur Acad Dermatol Venereol 2012;doi: 10.1111/jdv.12046; [Epub ahead of print]
96. Lebwohl M, Papp K, Han C, et al. Ustekinumab improves health-related quality of life in patients with moderate-to-severe psoriasis: Results from the PHOENIX 1 trial. Br J Dermatol 2010;162(1):137-46
97. Langley RG, Feldman SR, Han C, et al. Ustekinumab significantly improves symptoms of anxiety, depression, and skin-related quality of life in patients with moderate-to-severe psoriasis: Results from a randomized, double-blind, placebo-controlled phase III trial. J Am Acad Dermatol 2010;63(3):457-65
98. Griffiths CE, Strober BE, van de Kerkhof P, et al. Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis. N Engl J Med 2010;362(2):118-28
99. Wolf P, Weger W, Legat FJ, et al. Treatment with 311-nm ultraviolet B enhanced response of psoriatic lesions in ustekinumab-treated patients: A randomized intraindividual trial. Br J Dermatol 2012;166(1):147-53
100. Papp KA, Griffiths CE, Gordon K, et al. Long-term safety of ustekinumab in patients with moderate-to-severe psoriasis: Final results from 5 years of follow-up. Br J Dermatol 2013;168(4):844-54
101. Ryan C, Leonardi CL, Krueger JG, et al. Association between biologic therapies for chronic plaque psoriasis and cardiovascular events: A meta-analysis of randomized controlled trials. JAMA 2011;306(8):864-71
102. Tzellos T, Kyrgidis A, Zouboulis CC. Re-evaluation of the risk for major adverse cardiovascular events in patients treated with anti-IL-12/23 biological agents for chronic plaque psoriasis: A meta-analysis of randomized controlled trials. J Eur Acad Dermatol Venereol 2013;27(5):622-7
103. Gottlieb AB, Leonardi C, Kerdel F, et al. Efficacy and safety of briakinumab vs. etanercept and placebo in patients with moderate to severe chronic plaque psoriasis. Br J Dermatol 2011;165(3):652-60
104. Reich K, Langley RG, Papp KA, et al. A 52-week trial comparing briakinumab with methotrexate in patients with psoriasis. N Engl J Med 2011;365(17):1586-96
105. Tzellos T, Kyrgidis A, Trigoni A, Zouboulis CC. Association of anti-IL-12/ 23 biologic agents ustekinumab and briakinumab with major adverse cardiovascular events. J Eur Acad Dermatol Venereol 2012;4(3):320-3
106. Langley RG, Papp K, Gottlieb AB, et al. Safety results from a pooled analysis of randomized, controlled phase II and III clinical trials and interim data from an open-label extension trial of the interleukin-12/23 monoclonal antibody, briakinumab, in moderate to severe psoriasis. J Eur Acad Dermatol Venereol 2012
107. Tsai TF, Ho V, Song M, et al. The safety of ustekinumab treatment in patients with moderate-to-severe psoriasis and latent tuberculosis infection. Br J Dermatol 2012;167(5):1145-52
108. Wu JJ. Briakinumab versus Methotrexate for Psoriasis. N Engl J Med 2012;366(4):379-80; author reply 80
109. Papp KA, Leonardi C, Menter A, et al. Brodalumab, an anti-interleukin-17- receptor antibody for psoriasis. N Engl J Med 2012;366(13):1181-9
110. Leonardi C, Matheson R, Zachariae C, et al. Anti-interleukin-17 monoclonal antibody ixekizumab in chronic plaque psoriasis. N Engl J Med 2012;366(13):1190-9
111. Zhu B, Edson-Heredia E, Cameron G, et al. Early clinical response as a predictor of subsequent response to ixekizumab treatment: Results from a phase 2 study of patients with moderate-to-severe plaque psoriasis. Br J Dermatol 2013
112. Hueber W, Patel DD, Dryja T, et al. Effects of AIN457, a fully human antibody to interleukin-17A, on psoriasis, rheumatoid arthritis, and uveitis. Sci Transl Med 2010;2(52):52ra72
113. Papp KA, Langley RG, Sigurgeirsson B, et al. Efficacy and safety of secukinumab in the treatment of moderate-to-severe plaque psoriasis: A randomized, double-blind, placebo-controlled phase II dose-ranging study. Br J Dermatol 2013;168(2):412-21
114. Rich P, Sigurgeirsson B, Thaci D, et al. Secukinumab induction and maintenance therapy in moderate-to-severe plaque psoriasis: A randomized, double-blind, placebo-controlled, phase II regimen-finding study. Br J Dermatol 2013;168(2):402-11
115. Bankhead C. Psoriasis Yields to IL-23 Drug. 2013. Available from: Http://www.medpagetoday.com/ MeetingCoverage/AAD/37664 [Cited 28 August 2013]
116. Janssen, Inc. A study to evaluate CNTO 1959 in the treatment of patients with moderate to severe plaque-type psoriasis (X-PLORE). In: ClinicalTrials.gov [Internet]. National Library of Medicine (US), Bethesda (MD); 2000-2013. Available from: Http:// clinicaltrials.gov/ct2/show/ NCT01483599 NLM Identifier: NCT01483599
117. Janssen, Inc. A study of the efficacy, safety and tolerability of CNTO 1959, a human anti-IL 23 monoclonal antibody in participants with palmoplantar pustulosis. In: ClinicalTrials.gov [Internet]. National Library of Medicine (US), Bethesda (MD); 2000-2013. Available from: Http:// clinicaltrials.gov/ct2/ show/ NCT01845987 NLM Identifier: NCT01845987
118. Boehringer Ingelheim Pharmaceuticals. Single rising dose study of BI 655066 in patients with moderate and severe psoriasis. In: ClinicalTrials.gov [Internet]. National Library of Medicine (US), Bethesda (MD); 2000-2013. Available from: Http:// clinicaltrials.gov/ct2/show/ NCT01577550 NLM Identifier: NCT01577550
119. Wyeth; Pfizer. Study evaluating the safety and tolerability of ILV-094 in subjects with psoriasis. In: ClinicalTrials.gov [Internet]. National Library of Medicine (US), Bethesda (MD); 2000-2013. Available from: Http:// clinicaltrials.gov/ct2/show/ NCT00563524 NLM Identifier: NCT00563524
120. AbGenomics B.V Taiwan Branch. Phase IIa study of multiple doses of AbGn-168H by iv infusion in moderate to severe chronic plaque psoriasis patients. In: ClinicalTrials.gov [Internet]. National Library of Medicine (US), Bethesda (MD); 2000-2013. Available from: Http:// clinicaltrials.gov/ct2/show/ NCT01855880 NLM Identifier: NCT01855880
121. Biotest. Safety and efficacy of multiple doses of BT061 in patients with moderate to severe chronic plaque psoriasis. In: ClinicalTrials.gov [Internet]. National Library of Medicine (US), Bethesda (MD); 2000-2013. Available from: Http:// clinicaltrials.gov/ct2/show/ NCT01072383 NLM Identifier: NCT01072383
122. Imai A, Suzuki T, Sugitani A, et al. A novel fully human anti-CD40 monoclonal antibody, 4D11, for kidney transplantation in cynomolgus monkeys. Transplantation 2007;84(8):1020-8
123. Astellas Pharma Global Development, Inc. A multiple dose escalation study of ASKP1240 in subjects with moderate to severe plaque psoriasis. In: ClinicalTrials. gov [Internet]. National Library of Medicine (US), Bethesda (MD); 2000-2013. Available from: Http:// clinicaltrials.gov/ct2/show/ NCT01585233 NLM Identifier: NCT01585233
124. Mease PJ, Gladman DD, Ritchlin CT, et al. Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: Results of a double-blind, randomized, placebo-controlled trial. Arthritis Rheum 2005;52(10):3279-89
125. Mease PJ, Ory P, Sharp JT, et al. Adalimumab for long-term treatment of psoriatic arthritis: 2-year data from the Adalimumab Effectiveness in Psoriatic Arthritis Trial (ADEPT). Ann Rheum Dis 2009;68(5):702-9
126. Mease PJ, Kivitz AJ, Burch FX, et al. Etanercept treatment of psoriatic arthritis: Safety, efficacy, and effect on disease progression. Arthritis Rheum 2004;50(7):2264-72
127. Antoni CE, Kavanaugh A, Kirkham B, et al. Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: Results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT). Arthritis Rheum 2005;52(4):1227-36
128. McInnes IB, Kavanaugh A, Gottlieb AB, et al. Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial. Lancet 2013;382(9894):780-9
129. Mease PJ. Psoriatic arthritis -treatment update. Bull NYU Hosp Jt Dis 2011;69(3):243-9
130. Berthelot JM, De Bandt M, Goupille P, et al. Exposition to anti-TNF drugs during pregnancy: Outcome of 15 cases and review of the literature. Joint Bone Spine 2009;76(1):28-34
131. Smith CH, Anstey AV, Barker JN, et al. British Association of Dermatologists' guidelines for biologic interventions for psoriasis 2009. Br J Dermatol 2009;161(5):987-1019
132. Abramson A, Menter A, Perrillo R. Psoriasis, hepatitis B, and the tumor necrosis factor-alpha inhibitory agents: A review and recommendations for management. J Am Acad Dermatol 2012;67(6):1349-61
133. Chiu HY, Chen CH, Wu MS, et al. The safety profile of ustekinumab in the treatment of psoriasis patients with concurrent hepatitis B or hepatitis C. Br J Dermatol 2013;doi: 10.1111/bjd.12461; Epub ahead of print
134. Barco D, Puig L, Alomar A. [Treatment of moderate-severe psoriasis with etanercept in patients with chronic human immunodeficiency virus infection]. Actas Dermosifiliogr 2010;101(Suppl 1):77-81
135. Di Lernia V, Zoboli G, Ficarelli E. Long-term management of HIV/hepatitis C virus associated psoriasis with etanercept. Indian J Dermatol Venereol Leprol. 2013;79(3):444
136. Dreyer L, Mellemkjaer L, Andersen AR, et al. Incidences of overall and site specific cancers in TNFalpha inhibitor treated patients with rheumatoid arthritis and other arthritides -A follow-up study from the DANBIO Registry. Ann Rheum Dis 2013;72(1):79-82
137. Mellemkjaer L, Linet MS, Gridley G, et al. Rheumatoid arthritis and cancer risk. Eur J Cancer 1996;32A(10):1753-7
138. Galloway JB, Hyrich KL, Mercer LK, et al. Risk of septic arthritis in patients with rheumatoid arthritis and the effect of anti-TNF therapy: Results from the British Society for Rheumatology Biologics Register. Ann Rheum Dis 2011;70(10):1810-14
139. Giles JT, Bartlett SJ, Gelber AC, et al. Tumor necrosis factor inhibitor therapy and risk of serious postoperative orthopedic infection in rheumatoid arthritis. Arthritis Rheum 2006;55(2):333-7
140. Bibbo C, Goldberg JW. Infectious and healing complications after elective orthopaedic foot and ankle surgery during tumor necrosis factor-alpha inhibition therapy. Foot Ankle Int 2004;25(5):331-5
141. den Broeder AA, Creemers MC, Fransen J, et al. Risk factors for surgical site infections and other complications in elective surgery in patients with rheumatoid arthritis with special attention for anti-tumor necrosis factor: A large retrospective study. J Rheumatol 2007;34(4):689-95
142. Poss R, Thornhill TS, Ewald FC, et al. Factors influencing the incidence and outcome of infection following total joint arthroplasty. Clin Orthop Relat Res 1984(182):117-26
143. Reinstadler A, Mau N, Bhutani T, et al. Perioperative use of anti-tumor necrosis factor-alfa agents. J Am Acad Dermatol 2010;62(1):154-5
144. Mansouri B, Patel M, Menter A. Tumour necrosis factor-alpha inhibitor use in patients with psoriasis with organ transplantation. Br J Dermatol 2013;169(2):481-3
145. Ryan C, Menter A, Warren RB. The latest advances in pharmacogenetics and pharmacogenomics in the treatment of psoriasis. Mol Diag Ther 2010;14(2):81-93
146. Strober BE, Armour K, Romiti R, et al. Biopharmaceuticals and biosimilars in psoriasis: What the dermatologist needs to know. J Am Acad Dermatol 2012;66(2):317-22
147. Warren RB, Chalmers RJ, Griffiths CE, Menter A. Methotrexate for psoriasis in the era of biological therapy. Clin Exp Dermatol 2008;33(5):551-4
148. Talamonti M, Botti E, Galluzzo M, et al. Pharmacogenetics of psoriasis: HLA-Cw6 but not LCE3B/3C deletion nor TNFAIP3 polymorphism predisposes to clinical response to interleukin 12/ 23 blocker ustekinumab. Br J Dermatol 2013;169(2):458-63
149. Prieto-Perez R, Cabaleiro T, Dauden E, Abad-Santos F. Gene polymorphisms that can predict response to anti-TNF therapy in patients with psoriasis and related autoimmune diseases. Pharmacogenomics J 2013;13(4):297-305
150. Sugiura K, Takemoto A, Yamaguchi M, et al. The majority of generalized pustular psoriasis without psoriasis vulgaris is caused by deficiency of interleukin-36 receptor antagonist. J Invest Dermatol 2013; 151
151. Huffmeier U, Watzold M, Mohr J, et al. Successful therapy with anakinra in a patient with generalized pustular psoriasis carrying IL36RN mutations. Br J Dermatol 2013; 153
152. Kothary N, Diak IL, Brinker A, et al. Progressive multifocal leukoencephalopathy associated with efalizumab use in psoriasis patients. J Am Acad Dermatol 2011;65(3):546-51
153. Colsman A, Carrascosa JM, Ferrandiz C, Simon JC. Successful treatment of recalcitrant palmoplantar psoriasis with efalizumab. J Eur Acad Dermatol Venereol 2008;22(9):1131-4
154. Prodanovich S, Ma F, Taylor JR, et al. Methotrexate reduces incidence of vascular diseases in veterans with psoriasis or rheumatoid arthritis. J Am Acad Dermatol 2005;52(2):262-7
155. Wu JJ, Poon KY, Channual JC, Shen AY. Association between tumor necrosis factor inhibitor therapy and myocardial infarction risk in patients with psoriasis. Arch Dermatol 2012;148(11):1244-50
156. Bigby M. The use of anti-interleukin-12/ 23 agents and major adverse cardiovascular events. Arch Dermatol 2012;148(6):753-4
157. Lebwohl M. Interleukin 12/23 agents and major adverse cardiovascular events. Arch Dermatol 2012;148(11):1329